These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23128975)

  • 1. Hypersensitivity reaction to intravenous but not oral tacrolimus.
    Nicolai S; Bunyavanich S
    Transplantation; 2012 Nov; 94(9):e61-3. PubMed ID: 23128975
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful switch to oral tacrolimus in a patient with hypersensitivity reaction to parenteral vitamin K, cyclosporine, and tacrolimus: A case report.
    Taghvaye-Masoumi H; Sadeghi K; Hadjibabaie M
    J Oncol Pharm Pract; 2020 Jun; 26(4):986-988. PubMed ID: 31446869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical considerations in the use of intravenous tacrolimus in hematopoietic stem cell transplantation patients.
    Bauters T; Rayner P; Therrien R; Van Lancker S; Bordon V; Le Cordroch M; Dhooge C; Benoit Y; Vandenbroucke J
    J Oncol Pharm Pract; 2015 Dec; 21(6):478-80. PubMed ID: 24748582
    [No Abstract]   [Full Text] [Related]  

  • 4. Unique Pharmacokinetics for Oral Tacrolimus Administration After Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia With Shwachman-Diamond Syndrome.
    Inoue Y; Uemura Y; Kosugi S; Kanno M; Sano F
    Am J Ther; 2024 May-Jun 01; 31(3):e318-e319. PubMed ID: 37831700
    [No Abstract]   [Full Text] [Related]  

  • 5. [Usefulness of a slow-release tacrolimus for a patient with tacrolimus-induced renal injury after hemopoietic stem cell transplantation].
    Hosonuma R; Fujiwara S; Sasazaki M; Hirata Y; Yamamoto C; Uesawa M; Oh I; Matsuyama T; Mori M; Ozawa K; Muroi K
    Rinsho Ketsueki; 2012 Apr; 53(4):469-71. PubMed ID: 22687983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus-Induced Diabetic Ketoacidosis After Allogeneic Bone Marrow Transplant.
    Solmaz S; Gökgöz Z; Gereklioğlu Ç; Yeral M; Boğa C; Özdoğu H
    Exp Clin Transplant; 2017 Dec; 15(6):702-703. PubMed ID: 26643544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus dose modification in patients receiving concomitant isavuconazole after hematopoietic stem cell transplantation.
    Trifilio S; Rubin H; Monacelli A; Mehta J
    J Oncol Pharm Pract; 2021 Jun; 27(4):857-862. PubMed ID: 32659173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unit.
    Bacopoulos AJ; Ho L; Yang A; Ng P; Dara C; Loach D; Deotare U; Michelis FV; Viswabandya A; Kim DD; Lipton JH; Messner HA; Thyagu S
    J Oncol Pharm Pract; 2021 Jan; 27(1):33-39. PubMed ID: 32183586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT.
    Oshima K; Sato M; Terasako K; Kimura S; Okuda S; Kako S; Kanda Y
    Bone Marrow Transplant; 2010 Apr; 45(4):781-2. PubMed ID: 19701249
    [No Abstract]   [Full Text] [Related]  

  • 10. Tacrolimus Immunosuppression Causes Drug-Induced Hypersensitivity Reactions in Liver-Transplant Patients: A 3-Case Report.
    Mavroudi A; Imvrios G; Xinias I; Cassimos D; Vagiotas L; Giouleme O
    Transplant Proc; 2021 Jun; 53(5):1731-1735. PubMed ID: 33962771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Polymorphism of Tacrolimus-Metabolizing Enzymes Associated With Impaired Absorption of Tacrolimus Following Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
    Matsuoka S; Tsutsumi Y; Kikuchi R; Ito S; Teshima T
    Transplant Proc; 2019 Apr; 51(3):998-1001. PubMed ID: 30979494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous PRES and TMA secondary to tacrolimus after allogeneic bone marrow transplant.
    Aruch DB; Renteria A
    Blood; 2015 Jun; 125(25):3963. PubMed ID: 26287041
    [No Abstract]   [Full Text] [Related]  

  • 13. [Leukocytosis induced by BH-AC administration--allergic reaction to Casteo oil HCO-60. A case report].
    Ohta S; Iwane S; Katsura T; Shimada M; Hayashi S
    Rinsho Ketsueki; 1985 Apr; 26(4):555-9. PubMed ID: 3862890
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
    Dvorak CC; Callard E; Agarwal R
    Bone Marrow Transplant; 2006 Aug; 38(3):253-4. PubMed ID: 16785867
    [No Abstract]   [Full Text] [Related]  

  • 15. Polyoxyl 60 hydrogenated castor oil free nanosomal formulation of immunosuppressant Tacrolimus: pharmacokinetics, safety, and tolerability in rodents and humans.
    Ali SM; Ahmad A; Sheikh S; Ahmad MU; Rane RC; Kale P; Paithankar M; Saptarishi D; Sehgal A; Maheshwari K; Ahmad I
    Int Immunopharmacol; 2010 Mar; 10(3):325-30. PubMed ID: 20026256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Well-tolerated oral cyclosporine in a case of hypersensitivity to parenteral cyclosporine in postallogeneic bone marrow transplantation.
    Moeinian M; Sotoude H; Mohebbi Z; Asadollahi-Amin A; Mozafari R
    Indian J Pharmacol; 2018; 50(2):94-96. PubMed ID: 30100659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunosuppression and the problems in partial liver transplantation].
    Kawasaki M; Hashikura Y; Matsunami H; Makunouchi M
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):683. PubMed ID: 8963785
    [No Abstract]   [Full Text] [Related]  

  • 18. Topical tacrolimus.
    Frankel SJ; Kerdel FA
    Skin Therapy Lett; 2001; 6(4):1-2, 5. PubMed ID: 11176043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudo-Pelger-Huët anomaly in a patient on tacrolimus.
    Joneja U; Uppal G
    Blood; 2015 Jul; 126(2):277. PubMed ID: 26371350
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous Administration of Tacrolimus Stabilizes Control of Blood Concentration Regardless of CYP3A5 Polymorphism in Living Donor Liver Transplantation: Comparison of Intravenous Infusion and Oral Administration in Early Postoperative Period.
    Kato H; Usui M; Muraki Y; Okuda M; Nakatani K; Hayasaki A; Ito T; Iizawa Y; Murata Y; Tanemura A; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Isaji S
    Transplant Proc; 2018 Nov; 50(9):2684-2689. PubMed ID: 30401377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.